On December 14, the finals of the 2025 National Unicorn Enterprise Competition concluded successfully in Ningbo High-tech Zone. Yantai Zhigong Biopharmaceutical Technology Co., Ltd. stood out among nearly 140 shortlisted companies recommended by expert panels nationwide, thanks to its groundbreaking technological advances in the biopharmaceutical field. The company was awarded the “Technological Innovation Award” in this competition, earning a highly prestigious accolade for Yantai’s biopharmaceutical industry.

Good News | Zhigong Bio Wins the National Unicorn Enterprise Competition “Technology Innovation Award”

[Major Good News] On December 14, the finals of the 2025 National Unicorn Enterprise Competition concluded successfully in Ningbo High-tech Zone. Yantai Zhigong Biopharmaceutical Technology Co., Ltd. stood out thanks to its technological breakthroughs in the biopharmaceutical field, emerging from nearly… nationwide. 140 companies Shortlisted enterprises recommended through expert review Standing out from the crowd, successfully winning This time Event The “Technological Innovation Award” has earned the Yantai biopharmaceutical industry a highly prestigious accolade.

As a focus A national-level platform for pre‑IPO technology companies characterized by “high innovation, high growth, high integration, and high potential,” this year’s competition was co‑hosted by the Torch High‑Tech Industry Development Center of the Ministry of Industry and Information Technology and the China Electronics Society, bringing together leading enterprises from more than ten cutting‑edge sectors, including next‑generation information technology, high‑end equipment, and biopharmaceuticals. After three months of rigorous, multi‑stage selection, Zhigong Bio emerged as a standout, earning high praise from the expert panel thanks to its robust technological capabilities among nearly 140 finalists.

Zhigong Bio: Deeply committed to the diagnosis and treatment of bladder cancer. “The No-Man’s Land,” achieved through systemic innovation Industry Recognition

Zhigong Bio has consistently focused on addressing unmet clinical needs in bladder cancer diagnosis, dedicating itself to genomic research and the development of early‑diagnosis technologies in this field. The company has established a comprehensive product R&D and industrialization platform spanning bladder cancer risk prediction, early screening, early diagnosis, treatment‑guidance, and prognosis monitoring. Its distinctive core technology platform has demonstrated clear industry leadership in competitive settings.

This award represents an authoritative recognition of Zhigong Bio’s technological innovation capabilities and its clinically‑oriented R&D strategy. The company stated that it will seize this opportunity to further increase R&D investment, accelerate the translation of scientific breakthroughs into clinical applications, and continue to deepen its expertise in cutting‑edge biopharmaceutical fields—targeting unmet clinical needs and striving to grow into a nationally recognized “specialized, refined, distinctive, and innovative” enterprise. The “Little Giant” enterprises are steadily advancing toward their goals.